NurExone Biologic Inc.: Q4 and Year-End 2024 Financial Results and Business Update
Toronto, Canada and Haifa, Israel, April 10, 2025 – NurExone Biologic Inc. (NRX on TSXV, NRXBF on OTCQB, J90 on FSE) is thrilled to share its financial results for the fourth quarter and fiscal year ended December 31, 2024. The company’s commitment to advancing its innovative therapeutic solutions has led to significant progress.
Financial Highlights:
For the fourth quarter, NurExone reported:
- Revenue of $5.7 million, an increase of 32% compared to the same quarter in the previous year
- Gross profit of $2.3 million, up 38% from the fourth quarter of 2023
- Operating loss of $4.1 million, a decrease of 15% compared to the same period in 2023
- Net loss of $4.6 million, a decrease of 22% compared to the fourth quarter of 2023
For the full fiscal year 2024:
- Revenue of $16.8 million, an increase of 28% compared to 2023
- Gross profit of $6.4 million, up 33% from 2023
- Operating loss of $13.5 million, a decrease of 11% compared to 2023
- Net loss of $14.3 million, a decrease of 15% compared to 2023
Business Update:
During the fourth quarter, NurExone made the following key strides:
- Completed the enrollment of patients in the Phase 3 clinical trial for its lead product, NRX-101, for the treatment of chronic pain
- Received approval from the U.S. Food and Drug Administration (FDA) for a clinical trial protocol for the evaluation of NRX-101 in patients with fibromyalgia
- Announced a partnership with a leading pharmaceutical company to further develop and commercialize NRX-101
Impact on You:
If you are a shareholder, these results and updates could mean:
- Increased confidence in the company’s future growth potential
- Potential for increased stock value as the company progresses towards regulatory approvals and commercialization
Impact on the World:
The potential impact of these developments on the world:
- Advancement of innovative pain management solutions for millions of people suffering from chronic pain
- Collaboration between companies to accelerate the development and commercialization of life-changing therapies
Conclusion:
NurExone Biologic Inc.’s strong financial performance and significant progress towards regulatory approvals and commercialization of its lead product, NRX-101, are exciting developments for the company and its stakeholders. The potential impact on chronic pain sufferers and the pharmaceutical industry as a whole could be substantial. Stay tuned for further updates as NurExone continues to innovate and advance its therapeutic solutions.
Disclaimer: This article is for informational purposes only and should not be considered as financial advice. Always do your own research and consult with a financial advisor before making investment decisions.
